For COVID-19 vaccine updates, please review our information guide. For patient eligibility and scheduling availability, please visit VaccineTogetherNY.org.
Population Health Sciences

You are here

Publications

Found 255 results
Author Title Type [ Year(Asc)]
Filters: First Letter Of Last Name is B  [Clear All Filters]
2020
Ezeomah C, Cunningham KA, Stutz SJ, Fox RG, Bukreyeva N, Dineley KT, Paessler S, Cisneros IE.  2020.  Fentanyl self-administration impacts brain immune responses in male Sprague-Dawley rats.. Brain Behav Immun.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Breen WG, S Anderson K, Carrero XW, Brown PD, Ballman KV, O'Neill BP, Curran WJ, Abrams RA, Laack NN, Levitt R et al..  2020.  Final report from intergroup NCCTG 86-72-51 (Alliance): a phase 3 randomized clinical trial of high dose versus low dose radiation for adult low-grade glioma.. Neuro Oncol.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Liu J, van der Smissen WJCPrager, J Collée M, Bolla MK, Wang Q, Michailidou K, Dennis J, Ahearn TU, Aittomäki K, Ambrosone CB et al..  2020.  Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk.. Sci Rep. 10(1):9688.
Behrends CN, Gutkind S, Deming R, Fluegge KR, Bresnahan MP, Schackman BR.  2020.  Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.. J Urban Health.
Behrends CN, Gutkind S, Deming R, Fluegge KR, Bresnahan MP, Schackman BR.  2020.  Impact of Removing Medicaid Fee-for-Service Hepatitis C Virus (HCV) Treatment Restrictions on HCV Provider Experience with Medicaid Managed Care Organizations in New York City.. J Urban Health.
Benkeser D, Díaz I, Luedtke A, Segal J, Scharfstein D, Rosenblum M.  2020.  Improving Precision and Power in Randomized Trials for COVID-19 Treatments Using Covariate Adjustment, for Binary, Ordinal, and Time-to-Event Outcomes.. medRxiv.
Bowen DJ, Bao Y, Sirey JAnne, Ratzliff ADH.  2020.  Integrated behavioral health treatments: innovations to achieve population impact.. Transl Behav Med.
Bowen DJ, Bao Y, Sirey JAnne, Ratzliff ADH.  2020.  Integrated behavioral health treatments: innovations to achieve population impact.. Transl Behav Med.